Joseph P. Lyssikatos Sells 5,030 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph P. Lyssikatos sold 5,030 shares of Enliven Therapeutics stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $20.07, for a total value of $100,952.10. Following the transaction, the insider now owns 992,658 shares in the company, valued at approximately $19,922,646.06. This represents a 0.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Enliven Therapeutics Trading Down 3.4 %

Enliven Therapeutics stock opened at $19.69 on Wednesday. The company has a market capitalization of $966.11 million, a price-to-earnings ratio of -10.36 and a beta of 1.07. The stock’s 50 day moving average is $19.16 and its 200-day moving average is $22.26. Enliven Therapeutics, Inc. has a 12 month low of $13.30 and a 12 month high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.07. The business had revenue of $0.03 million during the quarter. As a group, equities research analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright lifted their price target on Enliven Therapeutics from $37.00 to $39.00 and gave the company a “buy” rating in a research note on Friday, March 21st.

Institutional Investors Weigh In On Enliven Therapeutics

Large investors have recently modified their holdings of the business. Tower Research Capital LLC TRC raised its stake in Enliven Therapeutics by 230.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock worth $36,000 after acquiring an additional 1,114 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Enliven Therapeutics by 3,058.1% in the 1st quarter. GAMMA Investing LLC now owns 2,716 shares of the company’s stock valued at $53,000 after purchasing an additional 2,630 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Enliven Therapeutics during the 4th quarter valued at approximately $97,000. BNP Paribas Financial Markets acquired a new position in Enliven Therapeutics during the 4th quarter worth approximately $112,000. Finally, ExodusPoint Capital Management LP acquired a new position in Enliven Therapeutics during the 4th quarter worth approximately $200,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.